Exciting news travels from Washington University of St. Louis (WUSL), where two BrightFocus-funded Alzheimer’s researchers recently had their results published in major scientific journals. Both projects were directly funded by BrightFocus.
ARVO is made up of 12,750 vision and ophthalmology researchers from more than 80 countries (and growing). They're an eclectic group of clinical and basic researchers, including MDs, PhDs, and other degrees (optometrists, osteopaths, veterinarians, and scientists at the master's and undergraduate levels).
University of California, Irvine (UCI) researchers, led by BrightFocus researcher Frank M. LaFerla, PhD, have published positive findings from mice studies that suggest cell therapy slows down brain changes and symptoms linked to Alzheimer’s disease.
A group of researchers based at the University of California, San Francisco (UCSF), have shown that when cardiovascular risk factors (CVRF) such as elevated glucose and high blood pressure begin in early adulthood, they are associated with significantly worse cognitive function in middle age compared with having no CVRF.
In an online report published April 2, 2014, BrightFocus researchers Matthew Campbell, PhD, Sarah Doyle, PhD, and Peter Humphries, PhD, and their teams, have reported from studies in mice that the inflammatory cytokine interleukin-18 (IL-18) can prevent choroidal neovascularization (CNV) formation—the fragile, leaky blood vessels forming on the retina that are the hallmark of wet AMD—and is not toxic to the retinal pigment epithelium.